Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Issued (in shares) Class Of Warrant Or Right, Issued In Period Class Of Warrant Or Right, Issued In Period Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Jay Venkatesan and Trusts Affiliated With Jay Venkatesan Jay Venkatesan and Trusts Affiliated With Jay Venkatesan [Member] Jay Venkatesan and Trusts Affiliated With Jay Venkatesan Document Fiscal Year Focus Document Fiscal Year Focus Adjustment to Compensation, Amount Adjustment to Compensation Amount Segment Reporting [Abstract] Segment Reporting [Abstract] Common stock, $0.01 par value per share; 300,000,000 shares authorized; 21,916,024 shares and 17,814,762 shares issued at June 30, 2026 and December 31, 2025, respectively; 21,901,569 and 17,800,307 outstanding as of June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued compensation and benefits Employee-related Liabilities, Current Ownership maximum (as a percent) Class of Warrant or Right, Ownership Percent Maximum Class of Warrant or Right, Ownership Percent Maximum Entity Ex Transition Period Entity Ex Transition Period Restatement Determination Date Restatement Determination Date Other long-term prepaid assets Prepaid Expense Other, Noncurrent January Offering January Offering [Member] January Offering Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Reportable Segment Reportable Segment [Member] Reportable Segment Issuance of common stock upon settlement of restricted stock and common warrants (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Number of shares of common stock to purchase (up to) (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Employee related research and development expenses Employee Related Reasearch and Development [Member] Employee Related Reasearch and Development Schedule of Prepaid and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Amendment Flag Amendment Flag Current liabilities Liabilities, Current [Abstract] Project [Axis] Project [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Class of Warrant or Right [Table] Class of Warrant or Right [Table] July Pre-Funded Warrants and July Common Warrants July Pre-Funded Warrants and July Common Warrants [Member] July Pre-Funded Warrants and July Common Warrants Change in fair value of warrant liabilities Change in fair value of warrant liabilities Fair Value Adjustment of Warrants Elicio Warrants Elicio Warrants [Member] Elicio Warrants Weighted average strike price Measurement Input, Strike Price [Member] Measurement Input, Strike Price Leases [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Number of research grant agreements Number Of Research Grant Agreements Number Of Research Grant Agreements Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Assets, Fair Value Disclosure [Abstract] Assets, Fair Value Disclosure [Abstract] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Weighted average common shares and pre-funded warrants outstanding, basic (in shares) Weighted average of common shares and pre-funded warrants outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Contract and grant reimbursements Recovery of Direct Costs Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four July Share And July Common Warrant July Shares And July Common Warrant [Member] July Shares And July Common Warrant Entity Address, City or Town Entity Address, City or Town RSUs granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Class of Stock [Axis] Class of Stock [Axis] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Royalty expense Royalty Expense Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Warrant Liability Warrant Liability [Member] Warrant Liability Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Warrant liabilities Warrant Liability Warrant Liability Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Inducement 2024 Plan Inducement 2024 Plan [Member] Inducement 2024 Plan Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Accrued interest Accrued Interest Accrued Interest Recently Adopted Accounting Standards During the Period and Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Deferred research obligation Increase (Decrease) in Contract with Customer, Liability Schedule of Segment Reporting Information, by Segment Segment Reporting [Table Text Block] Conversion of senior note payable Amortization of Debt Issuance Costs Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Debt Instrument, Redemption, Period Two Debt Instrument, Redemption, Period Two [Member] Exercise price (in dollars per share) Weighted average exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Schedule of Maturities of Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Commitments and Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure Debt instrument, face amount Debt Instrument, Face Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Common Stock and Stockholders' Equity Equity [Text Block] Conversion of Stock, Name [Domain] Conversion of Stock, Name [Domain] Security Exchange Name Security Exchange Name Treasury stock, at cost, 14,455 shares outstanding Treasury Stock, Common, Value Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Total liabilities Liabilities, Fair Value Disclosure Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Shares authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Operating lease liability, current Less: operating lease liability, current portion Operating Lease, Liability, Current Royalty rates (as a percent) Royalty Rate, Percent Royalty Rate, Percent Schedule of Property and Equipment, Net Property, Plant, and Equipment [Table Text Block] Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Net proceeds Sale of Stock, Consideration Received on Transaction, Net Of Issuance Costs Sale of Stock, Consideration Received on Transaction, Net Of Issuance Costs Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] RSUs exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Total liabilities Liabilities Trading Symbol Trading Symbol Geographical [Domain] Geographical [Domain] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Unrecognized compensation related to unvested stock option awards Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] July 2024 Common Warrants One July Common Warrant One [Member] July Common Warrant One Fair value of common warrants issued with January 2025 Offering Warrant Issued, Stock Issuance Fair Value Of Common Warrants Issued With January 2025 Offering Income Tax Disclosure [Abstract] Related Party Transactions [Abstract] Cash flows from operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Fair value of common warrants issued with June 2025 Promissory Note Warrant Issued, Debt Issuance Warrant Issued, Debt Issuance Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Shares issuable upon the exercise of warrants (excluding pre-funded warrants) Warrant [Member] Weighted average common shares and pre-funded warrants outstanding, diluted (in shares) Weighted average of common shares and pre-funded warrants outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted Average Remaining Contractual Life (years) Class of Warrant or Right, Weighted Average Remaining Contractual Terms Class of Warrant or Right, Weighted Average Remaining Contractual Terms Reimbursement from grant funds Research And Development Arrangement, Reimbursement from Grant Funds Research And Development Arrangement, Reimbursement from Grant Funds Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Less present value discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other long-term prepaid assets Increase (Decrease) in Other Noncurrent Assets Proceeds from secured lines of credit Proceeds from Secured Lines of Credit Professional fees and other general and administrative expenses Other General and Administrative Expense Operating cash outflows from operating leases Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Treasury Stock Treasury Stock, Common [Member] Project [Domain] Project [Domain] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Proceeds from the exercise of common warrants Proceeds from Warrant Exercises Organization, Consolidation and Presentation of Financial Statements [Abstract] Total Lessee, Operating Lease, Liability, to be Paid Other research and development expenses Other [Member] Other Accrued clinical trial and research and development costs Accrued Clinical Trial And Research And Development Costs, Current Accrued Clinical Trial And Research And Development Costs, Current Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Warrants And Rights Outstanding [Abstract] Warrants And Rights Outstanding Operating lease liabilities Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] At-The-Market Equity Offering Sales Agreement 2026 At-The-Market Equity Offering Sales Agreement 2026 [Member] At-The-Market Equity Offering Sales Agreement 2026 Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Depreciation Depreciation Plan Name [Domain] Plan Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Scenario [Domain] Scenario [Domain] Number of Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Components of cash and cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Operating lease, right-of-use assets Operating Lease, Right-of-Use Asset Aggregate sales milestone payments per product Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product Schedule of Net Loss Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Segment Reporting Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date GKCC GKCC [Member] GKCC Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Effect of foreign currency on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Restricted cash Restricted Cash and Cash Equivalent Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Clinical trial expenses Clinical Trail [Member] Clinical Trail Options outstanding, weighted average remaining contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Boston, Massachusetts Boston, Massachusetts [Member] Boston, Massachusetts Options vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Stock issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Other income (expense) Other Income and Expenses [Abstract] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] June 2025 Warrants June 2025 Warrants [Member] June 2025 Warrants Shares sold in offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Debt discount Debt Instrument, Unamortized Discount (Premium), Net Schedule of Restricted Stock Unit, Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Exercise Price Award Exercise Price Issuance of common stock upon settlement of restricted stock and common warrants Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Related Party Transaction [Axis] Related Party Transaction [Axis] Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Future minimum annual maintenance payments Collaborative Arrangement, Future Minimum Maintenance Payments Collaborative Arrangement, Future Minimum Maintenance Payments 2026 Registration Statement 2026 Registration Statement [Member] 2026 Registration Statement Debt Debt Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] June 2025 Common Warrants June 2025 Common Warrants [Member] June 2025 Common Warrants Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Measurement Input Type [Domain] Measurement Input Type [Domain] Net proceeds Sale of Stock, Consideration Received on Transaction Total operating expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date University University [Member] University Counterparty Name [Domain] Counterparty Name [Domain] Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Total other income (expense), net Nonoperating Income (Expense) Prepaid insurance Prepaid Insurance Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Angion Warrants Angion Warrants [Member] Angion Warrants Operating lease liabilities Operating Lease, Liability Payments of stock issuance costs Payments of Stock Issuance Costs Insider Trading Policies and Procedures [Line Items] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Total prepaid and other current assets Prepaid Expense and Other Assets, Current July 2026 Registered Direct Offering July 2026 Registered Direct Offering [Member] July 2026 Registered Direct Offering Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Letter of Credit Letter of Credit [Member] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Advanced professional fees Advanced Professional Fees Advanced Professional Fees Dividend yield (per share) Measurement Input, Expected Dividend Rate [Member] Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Schedule of Antidilutive Securities Excluded From Computation of Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key Weighted Average Weighted Average [Member] Less: accumulated depreciation Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization All Adjustments to Compensation All Adjustments to Compensation [Member] Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Research Grants Research, Development, and Computer Software Disclosure [Text Block] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Income Statement [Abstract] Entity Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued expenses Increase (Decrease) In Accrued Expenses Increase (Decrease) In Accrued Expenses Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Black-Scholes Option-Pricing Model Following Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Number of Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] City Area Code City Area Code Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Unvested shares under restricted stock grants Restricted Stock [Member] At-The-Market Equity Offering Sales Agreement 2024 At-The-Market Equity Offering Sales Agreement 2024 [Member] At-The-Market Equity Offering Sales Agreement 2024 Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Subsequent Events Subsequent Events [Text Block] Amortization of right-of-use assets, operating leases Operating Lease, Right-of-Use Asset, Periodic Reduction Volatility (annual) Measurement Input, Price Volatility [Member] Name Forgone Recovery, Individual Name Research and Development [Abstract] Unrecognized compensation related to unvested stock option awards, period for recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] January Common Warrants January Common Warrants [Member] January Common Warrants Statement [Line Items] Statement [Line Items] Total assets Total segment assets Assets Entity [Domain] Entity [Domain] Conversion Of Convertible Preferred Stock Conversion Of Convertible Preferred Stock [Member] Conversion Of Convertible Preferred Stock Convertible Notes Payable Convertible Debt [Member] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development, Contract to Perform for Others [Table] Weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Interest expense Interest Expense, Nonoperating Schedule of Components of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Conversion of Convertible Debt Conversion Of Convertible Debt [Member] Conversion Of Convertible Debt Schedule of Quantitative Information Regarding Operating Leases Schedule Of Quantitative Information On Operating Leases [Table Text Block] Schedule Of Quantitative Information On Operating Leases Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Proceeds from issuance of common stock and common warrants from the January 2025 Offering, net of issuance costs Proceeds from Convertible Debt Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stock-based compensation expense Share-Based Payment Arrangement, Expense July Public Offering July Public Offering [Member] Public Offering Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercise of stock options (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] RSUs granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Domain] Subsequent Event Type [Domain] Accumulated Deficit Retained Earnings [Member] Operating lease liability, noncurrent Operating Lease, Liability, Noncurrent RSUs forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Sale of stock, beneficial ownership limitation, percentage Sale Of Stock, Beneficial Ownership Limitation, Percentage Sale Of Stock, Beneficial Ownership Limitation, Percentage Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Forfeited (unvested) (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Schedule of Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Net loss per common share, diluted (in dollars per share) Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued interest Interest Costs Capitalized Liabilities, Fair Value Disclosure [Abstract] Liabilities, Fair Value Disclosure [Abstract] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and development Research and Development Expense Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs Proceeds From Issuance Of Common Stock From At-The-Market Offerings, Net Of Issuance Costs Proceeds From Issuance Of Common Stock From At-The-Market Offerings, Net Of Issuance Costs Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Share-Based Payment Arrangement [Abstract] Cash flows from financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property and equipment, net Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Debt Instrument, Redemption, Period Three Debt Instrument, Redemption, Period Three [Member] Price per share of shares issued (in dollars per share) Shares Issued, Price Per Share Accrued interest Accrued Interest Premium For Convertible Preferred Stock Accrued Interest Premium For Convertible Preferred Stock Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Shares available for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Underlying Securities Award Underlying Securities Amount Purchase of Warrants Purchase Of Warrants [Member] Purchase Of Warrants Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Forfeited (unvested) (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-average discount rate—operating leases Operating Lease, Weighted Average Discount Rate, Percent Segment Reporting [Table] Segment Reporting [Table] Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Fair value of common stock warrants upon settlement Fair Value Of Common Stock Warrants Upon Settlement Fair Value Of Common Stock Warrants Upon Settlement Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Sale of Stock [Axis] Sale of Stock [Axis] Stock Option Activity, Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] July 2024 Public Offering July 2024 Public Offering [Member] Public Offering Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Balance, beginning of the period Balance, end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Warrants and rights outstanding Warrants and Rights Outstanding Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Related Party Transaction [Domain] Related Party Transaction [Domain] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Outstanding Warrants Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Issuance of common stock and warrants from the January 2025 Offering, net of issuance costs (in shares) Stock and Warrants Issued During Period, Shares, Preferred Stock and Warrants Stock and Warrants Issued During Period, Shares, Preferred Stock and Warrants Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Amortization of debt discount Other expense related to accretion of discount Amortization of Debt Discount (Premium) Treasury stock, shares outstanding (in shares) Treasury stock, beginning balance (in shares) Treasury stock, ending balance (in shares) Treasury Stock, Common, Shares Equity Components [Axis] Equity Components [Axis] Clinical trial expenses Product and Service [Domain] 2024 Registration Statement 2024 Registration Statement [Member] 2024 Registration Statement Class of Stock [Line Items] Class of Stock [Line Items] Stock Conversion Description [Axis] Stock Conversion Description [Axis] Entity Interactive Data Current Entity Interactive Data Current Pre-Funded Warrant July 2024 Pre-Funded Warrants Pre-Funded Warrant [Member] Pre-Funded Warrant Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Termination Date Trading Arrangement Termination Date Property, Plant, and Equipment [Line Items] Property, Plant, and Equipment [Line Items] July Common Warrants July 2024 Common Warrants July Common Warrants [Member] July Common Warrants January 2025 Public Offering January Public Offering [Member] January Public Offering Subsequent Events [Abstract] Grant income Grant Revenue, Nonoperating Grant Revenue, Nonoperating Conversion of Convertible Note and interest into equity Settlement Of Promissory Notes Payable Settlement Of Promissory Notes Payable Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Document Type Document Type Accrued expenses Total accrued expenses Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Debt instrument, prepayment fee prepaid (as a percent) Debt Instrument, Redemption Price, Percentage Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Options vested and exercisable, total intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event [Line Items] Subsequent Event [Line Items] Stockholders' equity: Statement of Stockholders' Equity [Abstract] Proceeds from issuance of long-term debt Proceeds from Issuance of Long-Term Debt Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name January 2025 Common Warrants January 2025 Common Warrants [Member] January 2025 Common Warrants Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Warrants, contractual term (in years) Warrants and Rights Outstanding, Term Commitments and contingencies - Note 9 Commitments and Contingencies Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Total property and equipment Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Warrants, measurement input Warrants and Rights Outstanding, Measurement Input Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Grant award Research And Development Arrangement, Grant Research And Development Arrangement, Grant Executive Category: Executive Category [Axis] At-the-Market Offering At-the-Market Offering [Member] At-the-Market Offering Research Grant Agreement with GIRF Sept. 2023 Research Grant Agreement With The Gastro-Intestinal Research Foundation (“GIRF”) Sept. 2023 [Member] Research Grant Agreement With The Gastro-Intestinal Research Foundation (“GIRF”) Sept. 2023 Counterparty Name [Axis] Counterparty Name [Axis] Furniture and fixtures Furniture and Fixtures [Member] Operating expenses: Operating Costs and Expenses [Abstract] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Options vested and exercisable, weighted average remaining contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term Research Grant Agreement with GIRF Aug. 2024 Research Grant Agreement With The Gastro-Intestinal Research Foundation (“GIRF”) August 2024 [Member] Research Grant Agreement With The Gastro-Intestinal Research Foundation (“GIRF”) August 2024 Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Award Type [Domain] Award Type [Domain] Prepaid research and development contract services Prepaid Research And Development Expenses Prepaid Research And Development Expenses Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount 2026 (remaining six months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Pre-funded warrants outstanding (in shares) Number of warrants outstanding (in shares) Class of Warrant or Right, Outstanding Fair Value Measurements Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Grant Income Grant Revenue [Policy Text Block] Grant Revenue Warrant liabilities Warrants, Fair Value Disclosure Warrants, Fair Value Disclosure Supplemental disclosure of noncash investing and financing activities: Supplemental Cash Flow Information [Abstract] Other prepaid expenses and other current assets Other Prepaid Expenses And Other Assets, Current Other Prepaid Expenses And Other Assets, Current Expected term in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term PEO Name PEO Name Geographical [Axis] Geographical [Axis] Leasehold improvements Leasehold Improvements [Member] Other segment items Segment Reporting, Other Segment Item, Amount Long-Lived Asset, Class [Axis] Long-Lived Asset, Class [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Legal Entity [Axis] Legal Entity [Axis] Liability Class [Axis] Liability Class [Axis] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash, cash equivalents and restricted cash at the beginning of the period Cash, cash equivalents, and restricted cash at the end of the period Total cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Accrued professional fees Accrued Professional Fees, Current Accounts payable Increase (Decrease) in Accounts Payable Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Senior Secured Convertible Promissory Note Senior Secured Convertible Promissory Note [Member] Senior Secured Convertible Promissory Note Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Description of the Business and Financial Condition Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Conversion of senior note payable into common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Employee Stock Employee Stock [Member] Leases Lessee, Operating Leases [Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Net loss per common share, basic (in dollars per share) Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Risk-free rate Measurement Input, Risk Free Interest Rate [Member] Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Long-term debt, net Long-Term Debt, Excluding Current Maturities Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Sale of stock, aggregate initial offering price Sale of Stock, Aggregate Initial Offering Price Sale of Stock, Aggregate Initial Offering Price Issuance of common warrants associated with June 2025 Promissory Note Adjustments to Additional Paid in Capital, Warrant Issued Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Restricted cash, noncurrent Restricted Cash, Noncurrent Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Warrants Warrants And Rights Outstanding [Text Block] Warrants And Rights Outstanding Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate March 2024 Pre-Funded Warrants March 2024 Pre-Funded Warrants [Member] March 2024 Pre-Funded Warrants Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Research Grant Agreement with GIRF Sept. 2022 Research Grant Agreement With The Gastro-Intestinal Research Foundation (“GIRF”) Sept. 2022 [Member] Research Grant Agreement With The Gastro-Intestinal Research Foundation (“GIRF”) Sept. 2022 Chemistry, manufacturing and controls expenses Translational Medicine and CMC [Member] Translational Medicine and CMC Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Alternative [Abstract] Equity Awards Adjustments Equity Awards Adjustments [Member] Total liabilities and stockholders' equity Liabilities and Equity The 2022 Plan The 2022 Plan [Member] The 2022 Plan July Pre-Funded Warrants July Pre-Funded Warrants [Member] July Pre-Funded Warrants Stock Option Shares issuable upon exercise of stock options Share-Based Payment Arrangement, Option [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Plan Name [Axis] Plan Name [Axis] Tabular List, Table Tabular List [Table Text Block] Additional paid-in capital Additional Paid in Capital Other accrued expenses Accrued Other Operating Liabilities, Current Accrued Other Operating Liabilities, Current Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Options outstanding, total intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value RSUs forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period General and administrative Employee related general and administrative expenses General and Administrative Expense Long-Lived Asset, Class [Domain] Long-Lived Asset, Class [Domain] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Share price (in dollars per share) Sale of Stock, Price Per Share Conversion of senior note payable into common stock Stock Issued During Period, Value, Conversion of Convertible Securities Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Commitments and Contingencies Disclosure [Table] Commitments and Contingencies Disclosure [Table] Commitments and Contingencies Disclosure Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Table] Adjustment to Compensation: Adjustment to Compensation [Axis] Class of Stock [Domain] Class of Stock [Domain] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Statement of Cash Flows [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total assets Assets, Fair Value Disclosure Name Measure Name Income Taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Equipment Equipment [Member] Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Operating lease, expense Operating Lease, Expense Company Selected Measure Amount Company Selected Measure Amount Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Current assets Assets, Current [Abstract] Weighted-average remaining lease term—operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Income tax provision (benefit) Income Tax Expense (Benefit) Foreign exchange transaction gain Gain (Loss), Foreign Currency Transaction, before Tax Award Timing Method Award Timing Method [Text Block] Net increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forecast Forecast [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Interest income Investment Income, Interest Proceeds from the June 2025 Promissory Note, net of issuance costs Proceeds from Notes Payable Options vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price The 2021 Plan The 2021 Plan [Member] The 2021 Plan Non-cash interest expense Interest Expense, Noncash Interest Expense, Noncash Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Issuance of common stock and warrants from the January 2025 Offering, net of issuance costs Issuance of Stock and Warrants for Services or Claims